I-Mab (NBP) Stock Price, News & Analysis

Company Overview

I-Mab is a biotechnology company focused on discovering, developing and commercializing innovative biologic medicines, with an emphasis on cancer and other serious diseases. The company’s research programs are primarily based on monoclonal antibodies, bispecific antibodies and other immune-based therapies designed to target tumor cells or modify the immune response.

I-Mab’s pipeline has included givastomig (also known as TJ-CD4B), a bispecific antibody designed to target Claudin 18.2 and activate 4-1BB immune signaling. The company has also developed or partnered on other investigational antibody programs, including therapies directed at CD38, CD47 and CD73. These programs have been evaluated for potential use in cancers such as gastric, gastroesophageal, pancreatic and blood cancers, although development status can vary by program and geography.

Founded in 2016, I-Mab originally operated as a China-based biopharmaceutical company and expanded its activities internationally through research, development and licensing collaborations. In recent years, the company has pursued a greater focus on global development and the United States market while restructuring or transferring certain China-related operations and assets. I-Mab has been associated with founder and Chairman Dr. Jingwu Zang and has operated research and corporate activities in both China and the United States.

Key Stats

• Today's Range: $1.33 to $1.36
• 50-Day Range: $1.34 to $2.00
• 52-Week Range: $1.31 to $6.79
• Volume: 252,910 shs
• Average Volume: 604,464 shs
• Market Capitalization: $156.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

I-Mab Stock Analysis - MarketRank™

I-Mab scored higher than 32% of companies evaluated by MarketBeat, and ranked 723rd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

I-Mab has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

I-Mab has a consensus price target of $9.00, representing about 564.2% upside from its current price of $1.36.

Amount of Analyst Coverage

I-Mab has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for I-Mab are expected to decrease in the coming year, from ($0.30) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of I-Mab is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of I-Mab is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

I-Mab has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.16% of the float of I-Mab has been sold short.

Short Interest Ratio / Days to Cover

I-Mab has a short interest ratio ("days to cover") of 17.09, which indicates bearish sentiment.

Change versus previous month

Short interest in I-Mab has recently increased by 4.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

I-Mab does not currently pay a dividend.

Dividend Growth

I-Mab does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for I-Mab this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, I-Mab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $92,317.00 in company stock.

Percentage Held by Insiders

22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

38.38% of the stock of I-Mab is held by institutions.

Company Calendar

• Last Earnings: 8/20/2026
• Today: 10/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NBP
• CIK: 1778016
• Web: www.novabridge.com
• Phone: (301) 670-2800
• Fax: N/A
• Employees: 30
• Year Founded: 2016

Price Target and Rating

• Average Price Target for I-Mab: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +564.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.64
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.89 million
• Price / Sales: 40.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 115,650,000
• Free Float: 90,091,000
• Market Cap: $156.71 million
• Optionable: N/A
• Beta: 1.59